ClinicalTrials.gg
TerminatedNCT04181762SELUNEUpdated May 16, 2025Results posted

Study of Safety, Efficacy and Tolerability of Secukinumab Versus Placebo, in Combination With SoC Therapy, in Patients With Active Lupus Nephritis

A Phase 3 interventional study of secukinumab and Placebo in Lupus Nephritis, sponsored by Novartis Pharmaceuticals. Terminated at 105 sites in 34 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-05-16.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Why this study was terminated
Study terminated by sponsor due to futility analysis

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
275
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 10 studies in Lupus Nephritis by Novartis — 1 open to participants now, 3 under way, 2 of them phase 3. Lupus Nephritis · Novartis.

Started
2020
the only one that year
Phase 3
4 of 10
1 open now
Registered
3rd of 10
by date

Among the 10 studies in Lupus Nephritis by Novartis, this one is the only one that started in 2020, is one of 4 in phase 3, and was the 3rd registered.

Lupus Nephritis

343 studies on the registry are indexed under Lupus Nephritis; 136 are open to participants now.

Browse Lupus Nephritis studies →

Open to participants now

1 of the 10 studies in Lupus Nephritis by Novartis is open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 89 Lupus Nephritis studies recruiting now, 30 (34%) set no upper age limit and 52 (58%) stop at 75 or younger; 30 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Lupus Nephritis by Novartis, or all of them as a file.
02

Study summary

This was a pivotal, randomized, double-blind, placebo-controlled trial evaluating at Week 52 the efficacy and safety of secukinumab versus placebo in patients with active lupus nephritis (ISN/RPS Class III or IV, with or without co-existing class V features) also receiving background standard of care therapy (SoC).

Read the detailed description

The study consisted of the following parts:

  • Screening (up to 42 days/6 weeks)
  • Run-in period (optional): For subjects who received Mycophenolic acid (MPA) as SoC induction therapy as per investigator's decision and who were not already on MPA at Screening, MPA dosing was initiated during a run-in period before Randomization (for up to 4 weeks prior to the first dose of secukinumab)
  • Treatment Period: Duration of 104 weeks of treatment with secukinumab/placebo in addition to SoC treatment (with last dose given at Week 100)
  • Secukinumab dosing was started with initial dosing of 300 mg s.c. injections at Baseline, Weeks 1, 2, 3, and 4, followed by dosing every 4 weeks
  • Follow-up period: Duration of 8 weeks (last visit performed 12 weeks after last dose of study medication) for all except for subjects entering extension study CAIN457Q12301E1 (NCT05232864).

A total of 275 subjects were enrolled and were randomized to secukinumab 300 mg (n = 137) or placebo (n = 138) until study termination. Recruitment in this study was stopped on 26-May-2023. The CAIN457Q12301 study was terminated early by Novartis due to futile results from interim analysis 1 (IA1). There was no safety related reasons for early termination or concerns for the subjects in the study. The decision was made to terminate both the core and the related extension study in view of treatment futility of the core study.

03

Conditions studied

  • Lupus Nephritis

Keywords

  • Systemic Lupus Erythematosus (SLE)
  • Lupus Nephritis (LN)
  • secukinumab
  • renal biopsy
  • estimated Glomerular Filtration Rate (eGFR)
  • Urine Protein-to-Creatinine Ratio (UPCR)
  • Standard of Care (SoC) background therapy
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key inclusion criteria:

  1. Adult male and female subjects aged 18 - 75 years old at the time of Baseline.
  2. Confirmed diagnosis of:

    • SLE with documented history of at least 4 of the 11 criteria for SLE as defined by the American College of Rheumatology (ACR) (Tan et al 1982) revised by (Hochberg 1997). [NOTE: The 4 criteria did not have to be present at the time of Screening], OR
    • LN as the sole clinical criterion in the presence of ANA or anti-dsDNA antibodies.
  3. Active lupus nephritis, as defined by meeting the 4 following criteria:

    • within 6 months prior to Screening visit indicating active glomerulonephritis WHO or ISN/RPS Class III or IV LN [excluding III (C), IV-S (C) and IV-G (C)]; patients are permitted to have co-existing Class V. If no biopsy was performed within 6 months of screening, a biopsy was to be performed during the Screening period
    • UPCR ≥ 1 mg/mg at Screening.
    • > 30 mL/min/1.73 m2 by Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI).
    • Active urinary sediment (presence of cellular casts (RBC or WBC casts)) or hematuria (> 5 RBC per high power field or above the laboratory reference range).
  4. Subjects must have currently been on MPA, or willing to initiate SoC induction therapy for LN according to the institutional practices using MPA or low-dose CYC in addition to . For guidance, see published guidelines such as by (Bertsias et al 2012, Hahn et al 2012).
  5. Subjects must had been treated with anti-malarials (e.g. hydroxychloroquine), unless , and the dose had been stable for at least 10 days prior to Randomization.
  6. Able to provide signed .

Key Exclusion criteria:

  1. Severe renal impairment as defined by i.) Stage 4 CKD, or ii.) presence of oliguria (defined as a documented urine volume \< 400 mL/24 h), or iii.) ESRD required dialysis or transplantation.
  2. Known intolerance/ to MPA, or oral corticosteroids, or any component of the study drug(s).
  3. Subjects received any other biologic immunomodulatory therapy within 6 months prior to Screening, excluding belimumab where 3 months were acceptable.
  4. Previous exposure to secukinumab (AIN457) or any other biologic drug targeting IL-17 or the IL-17 receptor.
  5. Subjects received any drug within 1 month or five times the half-life of enrollment, whichever was longer.
  6. Receipt of more than 3000 mg i.v. pulse methylprednisolone (cumulative dose) within the 12 weeks prior to Baseline.
  7. Treatment with a systemic calcineurin inhibitor (e.g. cyclosporine, tacrolimus) within 12 weeks prior to Baseline
  8. CYC use (i.v. or oral) within the month prior to Baseline.
  9. Subjects requiring dialysis within the previous 12 months before Screening.
  10. History of renal transplant.
  11. Any severe progressive or uncontrolled concurrent medical condition, including recent severe thromboembolic events, that, in the opinion of the principal investigator, renders the subject unsuitable for the trial.
  12. Active ongoing inflammatory diseases that might confound the evaluation of the benefit of secukinumab therapy, including inflammatory bowel disease.
  13. Presence of investigator-identified significant medical problems which at the investigator's discretion would prevent the subject from participating in the study, included but not limited to the following: myocarditis, pericarditis, poorly controlled seizure disorder, acute confusional state, depression, severe manifestations of neuropsychiatric SLE (NPSLE).
  14. Chest X-ray, computerized tomography (CT) scan, or MRI with evidence of ongoing infectious or malignant process, obtained within 3 months preceding the Screening visit and evaluated by a qualified physician.
  15. History of chronic, recurrent systemic infections, active tuberculosis infection, or active systemic infections during the last two weeks (exception: common cold) prior to Randomization.
  16. Known infection with (HIV), or at Screening or Randomization.
  17. History of lymphoproliferative disease or any known or history of malignancy of any organ system treated or untreated within the past 5 years, regardless of whether there was evidence of local recurrence or (except for skin Bowen's disease or basal cell carcinoma or actinic keratoses that had been treated with no evidence of recurrence in the past 12 weeks, carcinoma in situ of the cervix or non-invasive malignant colon polyps that had been removed).
  18. Any of the following abnormal laboratory values on Screening evaluations as reported by Central Laboratory:

    • (AST), alanine aminotransferase (ALT), or amylase > 2.5xULN
    • \< 8g/dL
    • Neutrophils \< 1.0 x 109/L
    • count \< 50 x 109/L
  1. Pregnant or lactating women. 22. Women of , defined as all women physiologically capable of becoming pregnant, unless they were using highly effective methods of during the entire study or longer if required by locally approved prescribing information (e.g., in European Union (EU) 20 weeks). Of note: the highly effective methods of contraception were mandated due to SoC medications used as per protocol (MPA and CYC).

In case local regulations deviated from the contraception methods listed above, local regulations applied and were described in the informed consent form (ICF).

If stricter female or male contraception requirements were specified in the country-specific label for induction and maintenance standard of care medications, they had to be followed.

Note: Women were considered and not of childbearing potential if they had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g., age appropriate, history of vasomotor symptoms) or had surgical bilateral oophorectomy (with or without hysterectomy), total hysterectomy or tubal ligation at least six weeks prior to enrollment. In the case of oophorectomy alone, only when the reproductive status of the woman had been confirmed by follow-up hormone level assessment was she considered not of childbearing potential.

Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
275 participants (actual)

Study arms

  • Experimental
    secukinumab

    A blinded, weekly, subcutaneous (s.c.) secukinumab 300 mg loading regimen was administered for the first 4 weeks followed by a monthly maintenance dose in all randomized subjects thereafter.

    Drug: secukinumab

  • Placebo comparator
    placebo

    A blinded, weekly, subcutaneous (s.c.) matching placebo loading regimen was administered for the first 4 weeks followed by a monthly maintenance dose in all randomized subjects thereafter.

    Drug: Placebo

Interventions

  • STUDY DRUG

    Also known as: AIN457

  • DrugPlacebo

    Placebo

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving Complete Renal Response (CRR) at Week 52

    Complete Renal Response (CRR) is a composite endpoint defined as: * Estimated Glomerular Filtration Rate (eGFR) \>= 60 mL/min/1.73 m\^2 or no less than 85% of core Baseline values and * 24-hour Urine-to-Protein Creatinine Ratio (UPCR) =\< 0.5mg/mg * No treatment discontinuation before Week 52 * The subject did not receive more than 10 mg/day prednisone or equivalent for \>= 3 consecutive days or for \>= 7 days in total during Week 44 through Week 52. Non-responder imputation (NRI) was used for participants who did not have the required data to compute responses at Week 52 or who had discontinued study treatment before Week 52. A logistic regression model was used for the analysis of this endpoint.

    Time frame: Baseline, Week 52

Secondary outcomes

  1. Change From Baseline in 24-hour Urine Protein-to Creatinine Ratio (UPCR)

    Urine Protein-to-Creatinine Ratio (UPCR) was determined by a central laboratory by dividing the protein concentration by the creatinine concentration as measured in the urine collected (24-hour urine collection sample).

    Time frame: Baseline, Week 52

  2. Percentage of Participants Achieving Partial Renal Response (PRR) at Week 52

    Partial Renal Response (PRR) is a composite endpoint defined as: * \>= 50% reduction in 24-hour Urine-to-Protein Creatinine Ratio (UPCR) to sub-nephrotic levels (=\< 3 mg/mg) and * Estimated Glomerular Filtration Rate (eGFR) \>= 60 mL/min/1.73 m\^2 or no less than 85% of Baseline

    Time frame: Baseline, Week 52

  3. Average Daily Dose of Oral Corticosteroids

    Average daily dose of oral corticosteroids doses was used to assess efficacy of secukinumab compared to placebo in the averaged daily dose of oral corticosteroids administered between Week 16 and Week 52.

    Time frame: Week 16 to Week 52

  4. Percentage of Participants Achieving Partial Renal Response (PRR) at Week 24

    Partial Renal Response (PRR) is a composite endpoint defined as: * \>= 50% reduction in 24-hour Urine-to-Protein Creatinine Ratio (UPCR) to sub-nephrotic levels (=\< 3 mg/mg) and * Estimated Glomerular Filtration Rate (eGFR) \>= 60 mL/min/1.73 m\^2 or no less than 85% of Baseline

    Time frame: Baseline, Week 24

  5. Incidence Rate of Participants Achieving Complete Renal Response (CRR) up to Week 52

    Time to achieve Complete Renal Response (CRR) up to week 52 was evaluated by 4-week interval by using Kaplan-Meier estimates. Participants who did not achieve CRR were censored at the date of their last non-missing CRR result (including participants who completed week 52 without achieving CRR). * Subjects at risk = Subjects who did not achieve CRR and were not censored before or at the start of the specified interval. Participants had an event when achieving CRR. * Incidence rate (%) = (number of subjects with event/number of subjects at risk) x 100.

    Time frame: Baseline to Week 52

  6. Incidence Rate of Participants Achieving Partial Renal Response (PRR) up to Week 52

    Time to achieve Partial Renal Response (PRR) up to week 52 was evaluated by 4-week interval by using Kaplan-Meier estimates. Participants who did not achieve PRR were censored at the date of their last non-missing PRR result (including participants who completed week 52 without achieving PRR). Participants had event when achieving PRR. * Subjects at risk = Subjects who did not achieve PRR and were not censored before or at the start of the specified interval. * Incidence rate (%) = (number of subjects with event/ number of subjects at risk) x 100.

    Time frame: Baseline to Week 52

  7. Time to Achieve First Morning Void Urine Protein-to-Creatinine Ratio (UPCR) <= 0.5 mg/mg up to Week 52

    Time to achieve first morning void Urine Protein-to-Creatinine Ratio (UPCR) \<= 0.5 mg/mg up to week 52 was evaluated by 4-week interval by using Kaplan-Meier estimates. Participants who did not achieve UCPR were censored at the date of their last non-missing UCPR result (including participants who completed week 52 without achieving UCPR). Participants had event when achieving UCPR. * Subjects at risk = Subjects who did not achieve UCPR and were not censored before or at the start of the specified interval. * Incidence rate (%) = (number of subjects with event/ number of subjects at risk) x 100.

    Time frame: Baseline to Week 52

  8. Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-Fatigue) Mean Change From Baseline up to Week 52

    The FACIT-Fatigue is a 13-item questionnaire that assesses self-reported fatigue and its impact upon daily activities and function over the past week. The purpose of the FACIT-Fatigue in this study was to assess the impact of fatigue on subjects with lupus nephritis (LN). The level of fatigue was measured on a 5-point Likert scale (0 = not at all, 1 = a little bit, 2 = somewhat, 3 = quite a bit, 4 = very much) based on their experience of fatigue during the past 2 weeks. The scale score is computed by summing the item scores, after reversing those items that are worded in the negative direction. FACIT-Fatigue scale score range from 0 to 52, where higher scores represent less fatigue.

    Time frame: Baseline, Week 12, Week 24, Week 36, Week 52

  9. Short Form Health Survey (SF-36) Version 2 (Acute Form) Mean Change From Baseline in Physical Component Score (PCS) up to Week 52

    The SF-36 questionnaire consists of eight scales yielding two summary measures: physical and mental health. The physical health measure includes four scales of physical functioning (10 items), role-physical (4 items), bodily pain (2 items), and general health (5 items). The mental health measure is composed of vitality (4 items), social functioning (2 items), role-emotional (3 items), and mental health (5 items). In this trial, SF-36-PCS responder (improvement of \>= 2.5 points) were evaluated. Responses to items allow for direct calculation of scale scores, while the physical component summary (PCS) scores are computed from weighted scale scores. For all scales and summary measures, higher scores indicate better health outcomes (PCS scores range 0 to 100).

    Time frame: Baseline, Week 12, Week 24, Week 36, Week 52

  10. Lupus Quality of Life (LupusQoL) Physical Health Score Mean Change From Baseline up to Week 52

    The LupusQoL is a disease-specific, 34-item, self-report questionnaire designed to measure the health-related quality of life (HRQoL) of subjects with SLE within 8 domains (i.e., physical health (8 items), emotional health (6 items), body image (5 items), pain (3 items), planning (3 items), fatigue (4 items), intimate relationships (2 items), and burden to others (3 items)). Responses are based on a 5-point Likert scale where 0 (all of the time) to 4 (never). Each domain of the LupusQoL was scored separately. Transformed scores range from 0 (worst HRQoL) to 100 (best HRQoL).

    Time frame: Baseline, Week 12, Week 24, Week 36, Week 52

  11. Incidence of Adverse Events (AEs), Serious Adverse Events (SAEs)

    The distribution of adverse events was done via the analysis of frequencies for treatment emergent Adverse Event (TEAEs), Serious Adverse Event (TESAEs) and Deaths due to AEs, through the monitoring of relevant clinical and laboratory safety parameters.

    Time frame: From first dose of study treatment up to approximately 2 years

  12. Percentage of Participants With Complete Renal Response (CRR) at Week 104 Within Those Who Had Achieved CRR at Week 52 in the Secukinumab Group

    The percentage of participants with maintained renal response (CRR) at Week 104 in the secukinumab group was evaluated

    Time frame: Week 52 to Week 104

  13. Percentage of Participants With Improved or Maintained Response (PRR or CRR) at Week 104 in Those Who Had Achieved at Least PRR at Week 52 in the Secukinumab Group

    The percentage of participants with improved or maintained renal response (CRR) at Week 104 in the secukinumab group was evaluated

    Time frame: Week 52 to Week 104

07

Results

Posted Oct 10, 2024

Participant flow

This study was conducted in 106 centers in 34 countries worldwide.

Participant flow — Overall Study
MilestoneSecukinumab 300 mgPlacebo
Started137138
Full analysis set 29191
Pharmacokinetic set1360
Completed2323
Not completed114115
Withdrew: Adverse event13
Withdrew: Lost to follow-up11
Withdrew: Physician decision13
Withdrew: Pregnancy01
Withdrew: Lack of efficacy22
Withdrew: Study terminated by sponsor9597
Withdrew: Subject decision114
Withdrew: Death11
Withdrew: Protocol deviation10
Withdrew: Withdrawal of informed consent13

Outcome measures

PrimaryPercentage of Participants Achieving Complete Renal Response (CRR) at Week 52

Complete Renal Response (CRR) is a composite endpoint defined as: * Estimated Glomerular Filtration Rate (eGFR) \>= 60 mL/min/1.73 m\^2 or no less than 85% of core Baseline values and * 24-hour Urine-to-Protein Creatinine Ratio (UPCR) =\< 0.5mg/mg * No treatment discontinuation before Week 52 * The subject did not receive more than 10 mg/day prednisone or equivalent for \>= 3 consecutive days or for \>= 7 days in total during Week 44 through Week 52. Non-responder imputation (NRI) was used for participants who did not have the required data to compute responses at Week 52 or who had discontinued study treatment before Week 52. A logistic regression model was used for the analysis of this endpoint.

Time frame:
Baseline, Week 52
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving Complete Renal Response (CRR) at Week 52
Percentage of participantsSecukinumab 300 mgPlacebo
Percentage of Participants Achieving Complete Renal Response (CRR) at Week 5225.9 (16.8 to 34.9)38.6 (28.5 to 48.7)
Statistical analysis
  • Secukinumab 300 mg vs Placebo · Regression, Logistic · p = 0.0662 · Mean difference (final values): -12.7 · 95% CI -26.3 to 0.9Difference from placebo and 95% CI are from a logistic regression model with treatment group, stratification factor (SoC) and race as factors and baseline UPCR as a covariate using marginal standardization method.
SecondaryChange From Baseline in 24-hour Urine Protein-to Creatinine Ratio (UPCR)

Urine Protein-to-Creatinine Ratio (UPCR) was determined by a central laboratory by dividing the protein concentration by the creatinine concentration as measured in the urine collected (24-hour urine collection sample).

Time frame:
Baseline, Week 52
Reported as:
Mean · mg/mg
Change From Baseline in 24-hour Urine Protein-to Creatinine Ratio (UPCR)
mg/mgSecukinumab 300 mgPlacebo
Change From Baseline in 24-hour Urine Protein-to Creatinine Ratio (UPCR)-2.204 ± 3.5162-2.741 ± 5.9448
SecondaryPercentage of Participants Achieving Partial Renal Response (PRR) at Week 52

Partial Renal Response (PRR) is a composite endpoint defined as: * \>= 50% reduction in 24-hour Urine-to-Protein Creatinine Ratio (UPCR) to sub-nephrotic levels (=\< 3 mg/mg) and * Estimated Glomerular Filtration Rate (eGFR) \>= 60 mL/min/1.73 m\^2 or no less than 85% of Baseline

Time frame:
Baseline, Week 52
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving Partial Renal Response (PRR) at Week 52
Percentage of participantsSecukinumab 300 mgPlacebo
Percentage of Participants Achieving Partial Renal Response (PRR) at Week 5256.2 (44.1 to 67.8)63.9 (51.7 to 74.9)
Statistical analysis
  • Secukinumab 300 mg vs Placebo · Mean difference (final values): -7.7 · 95% CI -23.7 to 8.495% Confidence Intervals (CIs) are constructed using the exact binomial test.
SecondaryAverage Daily Dose of Oral Corticosteroids

Average daily dose of oral corticosteroids doses was used to assess efficacy of secukinumab compared to placebo in the averaged daily dose of oral corticosteroids administered between Week 16 and Week 52.

Time frame:
Week 16 to Week 52
Reported as:
Mean · mg/day
Average Daily Dose of Oral Corticosteroids
mg/daySecukinumab 300 mgPlacebo
Average Daily Dose of Oral Corticosteroids8.1243 ± 6.383297.4791 ± 5.61958
SecondaryPercentage of Participants Achieving Partial Renal Response (PRR) at Week 24

Partial Renal Response (PRR) is a composite endpoint defined as: * \>= 50% reduction in 24-hour Urine-to-Protein Creatinine Ratio (UPCR) to sub-nephrotic levels (=\< 3 mg/mg) and * Estimated Glomerular Filtration Rate (eGFR) \>= 60 mL/min/1.73 m\^2 or no less than 85% of Baseline

Time frame:
Baseline, Week 24
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving Partial Renal Response (PRR) at Week 24
Percentage of participantsSecukinumab 300 mgPlacebo
Percentage of Participants Achieving Partial Renal Response (PRR) at Week 2452.8 (42.9 to 62.5)43.6 (34.2 to 53.4)
SecondaryIncidence Rate of Participants Achieving Complete Renal Response (CRR) up to Week 52

Time to achieve Complete Renal Response (CRR) up to week 52 was evaluated by 4-week interval by using Kaplan-Meier estimates. Participants who did not achieve CRR were censored at the date of their last non-missing CRR result (including participants who completed week 52 without achieving CRR). * Subjects at risk = Subjects who did not achieve CRR and were not censored before or at the start of the specified interval. Participants had an event when achieving CRR. * Incidence rate (%) = (number of subjects with event/number of subjects at risk) x 100.

Time frame:
Baseline to Week 52
Reported as:
Number · Percentage of participants
Incidence Rate of Participants Achieving Complete Renal Response (CRR) up to Week 52
Percentage of participantsSecukinumab 300 mgPlacebo
1 to 28 days0.00.8
29 to 56 days0.00.0
57 to 84 days3.15.4
85 to 112 days11.716.8
113 to 140 days0.02.2
141 to 168 days0.03.4
169 to 196 days20.420.0
197 to 224 days1.40.0
225 to 252 days0.00.0
253 to 280 days14.83.6
281 to 308 days0.02.1
309 to 336 days0.00.0
337 to 364 days2.37.3
SecondaryIncidence Rate of Participants Achieving Partial Renal Response (PRR) up to Week 52

Time to achieve Partial Renal Response (PRR) up to week 52 was evaluated by 4-week interval by using Kaplan-Meier estimates. Participants who did not achieve PRR were censored at the date of their last non-missing PRR result (including participants who completed week 52 without achieving PRR). Participants had event when achieving PRR. * Subjects at risk = Subjects who did not achieve PRR and were not censored before or at the start of the specified interval. * Incidence rate (%) = (number of subjects with event/ number of subjects at risk) x 100.

Time frame:
Baseline to Week 52
Reported as:
Number · Percentage of participants
Incidence Rate of Participants Achieving Partial Renal Response (PRR) up to Week 52
Percentage of participantsSecukinumab 300 mgPlacebo
1 to 28 days0.00.8
29 to 56 days0.00.0
57 to 84 days7.05.4
85 to 112 days27.830.5
113 to 140 days1.32.6
141 to 168 days0.04.1
169 to 196 days32.414.9
197 to 224 days2.40.0
225 to 252 days2.60.0
253 to 280 days11.816.3
281 to 308 days4.02.9
309 to 336 days0.00.0
337 to 364 days0.06.5
SecondaryTime to Achieve First Morning Void Urine Protein-to-Creatinine Ratio (UPCR) <= 0.5 mg/mg up to Week 52

Time to achieve first morning void Urine Protein-to-Creatinine Ratio (UPCR) \<= 0.5 mg/mg up to week 52 was evaluated by 4-week interval by using Kaplan-Meier estimates. Participants who did not achieve UCPR were censored at the date of their last non-missing UCPR result (including participants who completed week 52 without achieving UCPR). Participants had event when achieving UCPR. * Subjects at risk = Subjects who did not achieve UCPR and were not censored before or at the start of the specified interval. * Incidence rate (%) = (number of subjects with event/ number of subjects at risk) x 100.

Time frame:
Baseline to Week 52
Reported as:
Number · Percentage of participants
Time to Achieve First Morning Void Urine Protein-to-Creatinine Ratio (UPCR) <= 0.5 mg/mg up to Week 52
Percentage of participantsSecukinumab 300 mgPlacebo
1 to 28 days19.321.3
29 to 56 days2.85.6
57 to 84 days8.77.0
85 to 112 days11.89.7
113 to 140 days7.67.4
141 to 168 days9.96.9
169 to 196 days9.73.2
197 to 224 days7.511.9
225 to 252 days4.26.0
253 to 280 days4.40.0
281 to 308 days12.24.5
309 to 336 days0.05.1
337 to 364 days3.12.9
SecondaryFunctional Assessment of Chronic Illness Therapy - Fatigue (FACIT-Fatigue) Mean Change From Baseline up to Week 52

The FACIT-Fatigue is a 13-item questionnaire that assesses self-reported fatigue and its impact upon daily activities and function over the past week. The purpose of the FACIT-Fatigue in this study was to assess the impact of fatigue on subjects with lupus nephritis (LN). The level of fatigue was measured on a 5-point Likert scale (0 = not at all, 1 = a little bit, 2 = somewhat, 3 = quite a bit, 4 = very much) based on their experience of fatigue during the past 2 weeks. The scale score is computed by summing the item scores, after reversing those items that are worded in the negative direction. FACIT-Fatigue scale score range from 0 to 52, where higher scores represent less fatigue.

Time frame:
Baseline, Week 12, Week 24, Week 36, Week 52
Reported as:
Mean · Unit on a scale
Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-Fatigue) Mean Change From Baseline up to Week 52
Unit on a scaleSecukinumab 300 mgPlacebo
Week 12-2.8 ± 8.47-1.9 ± 8.46
Week 24-1.4 ± 9.66-2.0 ± 8.93
Week 36-2.6 ± 9.21-2.1 ± 9.67
Week 52-2.0 ± 10.18-2.0 ± 9.51
SecondaryShort Form Health Survey (SF-36) Version 2 (Acute Form) Mean Change From Baseline in Physical Component Score (PCS) up to Week 52

The SF-36 questionnaire consists of eight scales yielding two summary measures: physical and mental health. The physical health measure includes four scales of physical functioning (10 items), role-physical (4 items), bodily pain (2 items), and general health (5 items). The mental health measure is composed of vitality (4 items), social functioning (2 items), role-emotional (3 items), and mental health (5 items). In this trial, SF-36-PCS responder (improvement of \>= 2.5 points) were evaluated. Responses to items allow for direct calculation of scale scores, while the physical component summary (PCS) scores are computed from weighted scale scores. For all scales and summary measures, higher scores indicate better health outcomes (PCS scores range 0 to 100).

Time frame:
Baseline, Week 12, Week 24, Week 36, Week 52
Reported as:
Mean · Unit on a scale
Short Form Health Survey (SF-36) Version 2 (Acute Form) Mean Change From Baseline in Physical Component Score (PCS) up to Week 52
Unit on a scaleSecukinumab 300 mgPlacebo
Week 122.306 ± 6.43062.210 ± 6.8760
Week 242.873 ± 6.45021.687 ± 6.5346
Week 362.910 ± 6.82343.152 ± 7.0623
Week 523.410 ± 7.71232.707 ± 6.8887
SecondaryLupus Quality of Life (LupusQoL) Physical Health Score Mean Change From Baseline up to Week 52

The LupusQoL is a disease-specific, 34-item, self-report questionnaire designed to measure the health-related quality of life (HRQoL) of subjects with SLE within 8 domains (i.e., physical health (8 items), emotional health (6 items), body image (5 items), pain (3 items), planning (3 items), fatigue (4 items), intimate relationships (2 items), and burden to others (3 items)). Responses are based on a 5-point Likert scale where 0 (all of the time) to 4 (never). Each domain of the LupusQoL was scored separately. Transformed scores range from 0 (worst HRQoL) to 100 (best HRQoL).

Time frame:
Baseline, Week 12, Week 24, Week 36, Week 52
Reported as:
Mean · Unit on a scale
Lupus Quality of Life (LupusQoL) Physical Health Score Mean Change From Baseline up to Week 52
Unit on a scaleSecukinumab 300 mgPlacebo
Week 125.32 ± 16.0316.18 ± 19.248
Week 244.84 ± 18.1845.55 ± 20.485
Week 365.59 ± 20.6847.89 ± 23.112
Week 527.62 ± 23.2758.55 ± 20.589
SecondaryIncidence of Adverse Events (AEs), Serious Adverse Events (SAEs)

The distribution of adverse events was done via the analysis of frequencies for treatment emergent Adverse Event (TEAEs), Serious Adverse Event (TESAEs) and Deaths due to AEs, through the monitoring of relevant clinical and laboratory safety parameters.

Time frame:
From first dose of study treatment up to approximately 2 years
Reported as:
Count of participants · Participants
Incidence of Adverse Events (AEs), Serious Adverse Events (SAEs)
ParticipantsSecukinumab 300 mgPlacebo
Deaths11
Serious Adverse Event (TESAEs)3039
Treatment Emergent Adverse Event (TEAEs)120123
TESAEs leading to study medication discontinuation810
SecondaryPercentage of Participants With Complete Renal Response (CRR) at Week 104 Within Those Who Had Achieved CRR at Week 52 in the Secukinumab Group

The percentage of participants with maintained renal response (CRR) at Week 104 in the secukinumab group was evaluated

Time frame:
Week 52 to Week 104
Reported as:
Count of participants · Participants
Percentage of Participants With Complete Renal Response (CRR) at Week 104 Within Those Who Had Achieved CRR at Week 52 in the Secukinumab Group
ParticipantsSecukinumab 300 mg
Achieve CRR5
Not Achieve CRR1
SecondaryPercentage of Participants With Improved or Maintained Response (PRR or CRR) at Week 104 in Those Who Had Achieved at Least PRR at Week 52 in the Secukinumab Group

The percentage of participants with improved or maintained renal response (CRR) at Week 104 in the secukinumab group was evaluated

Time frame:
Week 52 to Week 104
Reported as:
Count of participants · Participants
Percentage of Participants With Improved or Maintained Response (PRR or CRR) at Week 104 in Those Who Had Achieved at Least PRR at Week 52 in the Secukinumab Group
ParticipantsSecukinumab 300 mg
Achieve PRR or CRR11
Not achieve PRR or CRR1

Adverse events

Collected over On-treatment adverse events and deaths were reported from first dose of study treatment to 84 days after last dose of study medication, assessed up to approximately 2 years.. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Secukinumab 300 mg1/137 (0.7%)30/137 (21.9%)111/137 (81%)
Placebo1/138 (0.7%)39/138 (28.3%)116/138 (84.1%)
Most frequent serious events
Showing 10 of 68
Most frequent serious events
EventSecukinumab 300 mgPlacebo
PneumoniaInfections and infestations5/1373/138
Lupus nephritisRenal and urinary disorders4/1375/138
COVID-19Infections and infestations3/1374/138
Acute kidney injuryRenal and urinary disorders1/1374/138
CataractEye disorders2/1371/138
Pyelonephritis acuteInfections and infestations2/1371/138
Urinary tract infectionInfections and infestations0/1372/138
AnaemiaBlood and lymphatic system disorders1/1370/138
PancytopeniaBlood and lymphatic system disorders1/1370/138
DyspepsiaGastrointestinal disorders1/1371/138
Most frequent other events
Showing 10 of 82
Most frequent other events
EventSecukinumab 300 mgPlacebo
Urinary tract infectionInfections and infestations19/13730/138
Upper respiratory tract infectionInfections and infestations19/13726/138
COVID-19Infections and infestations25/13722/138
DiarrhoeaGastrointestinal disorders23/13721/138
HeadacheNervous system disorders21/13714/138
ArthralgiaMusculoskeletal and connective tissue disorders13/13719/138
CoughRespiratory, thoracic and mediastinal disorders8/13714/138
AnaemiaBlood and lymphatic system disorders12/13713/138
NauseaGastrointestinal disorders11/1375/138
NasopharyngitisInfections and infestations11/13711/138

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Secukinumab 300 mgPlaceboTotal
Mean34.1 ± 10.8433.2 ± 11.2833.6 ± 11.05
Age, Customized
Age, Customized(Participants)Secukinumab 300 mgPlaceboTotal
< 30 years5564119
>= 30 years8274156
Sex: Female, Male
Sex: Female, Male(Participants)Secukinumab 300 mgPlaceboTotal
Female116124240
Male211435
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Secukinumab 300 mgPlaceboTotal
American Indian or Alaska Native212142
Asian6756123
Native Hawaiian or Other Pacific Islander000
Black or African American6915
White425294
More than one race101
Unknown or Not Reported000
08

Study locations

105 sites
  • University Of Alabama
    Birmingham, Alabama 35294, United States
  • Kaiser Permanente Fontana
    Fontana, California 92335, United States
  • University of California LA
    Los Angeles, California 90095, United States
  • Arthritis and Rheum Dise Spec
    Aventura, Florida 33180, United States
  • Integral Rheumatology and Immunology Specialists IRIS
    Plantation, Florida 33324, United States
  • Piedmont Heart Institute
    Atlanta, Georgia 30309, United States
  • Beth Israel Deaconess Hospital
    Boston, Massachusetts 02215, United States
  • Ahmed Arif Medical Research Center
    Grand Blanc, Michigan 48439, United States
  • Novartis Investigative Site
    Caba, Buenos Aires C1280AEB, Argentina
  • Novartis Investigative Site
    Ciudad Autonoma de Bs As, Buenos Aires C1015ABO, Argentina
  • Novartis Investigative Site
    Cordoba, X5016JDA, Argentina
  • Novartis Investigative Site
    Westmead, New South Wales 2145, Australia
  • Novartis Investigative Site
    Fortaleza, CE 60430 370, Brazil
  • Novartis Investigative Site
    Porto Alegre, RS 90020-090, Brazil
  • Novartis Investigative Site
    Joinville, Santa Catarina 893227-680, Brazil
  • Novartis Investigative Site
    Santo Andre, SP 09090-790, Brazil
  • Novartis Investigative Site
    Sao Paulo, SP 04038-002, Brazil
  • Novartis Investigative Site
    Sao Paulo, SP 05403 000, Brazil
  • Novartis Investigative Site
    Sao Jose do Rio Preto, 15090 000, Brazil
  • Novartis Investigative Site
    Toronto, Ontario M5T 2S8, Canada
  • Novartis Investigative Site
    Valdivia, Los Rios 5100238, Chile
  • Novartis Investigative Site
    Santiago, RM 7500588, Chile
  • Novartis Investigative Site
    Concepcion, 6740, Chile
  • Novartis Investigative Site
    Santiago, 7500710, Chile
  • Novartis Investigative Site
    Nanning, Guangxi 530021, China
  • Novartis Investigative Site
    Shijiazhuang, Hebei 050000, China
  • Novartis Investigative Site
    Changsha, Hunan 410008, China
  • Novartis Investigative Site
    Nanchang, Jiangxi 330006, China
  • Novartis Investigative Site
    Binzhou, Shandong 256603, China
  • Novartis Investigative Site
    Chengdu, Sichuan 610072, China
  • Novartis Investigative Site
    Beijing, 100034, China
  • Novartis Investigative Site
    Beijing, 100730, China
  • Novartis Investigative Site
    Chongqing, 400037, China
  • Novartis Investigative Site
    Guangzhou, 510280, China
  • Novartis Investigative Site
    Shanghai, 200025, China
  • Novartis Investigative Site
    Shanghai, 200040, China
  • Novartis Investigative Site
    Wuhan, 430022, China
  • Novartis Investigative Site
    Medellin, Antioquia 050001, Colombia
  • Novartis Investigative Site
    Barranquilla, 080020, Colombia
  • Novartis Investigative Site
    Cali, 760012, Colombia
  • Novartis Investigative Site
    Cundinamarca, 111121, Colombia
  • Novartis Investigative Site
    Zagreb, 10000, Croatia
  • Novartis Investigative Site
    Praha 2, 128 50, Czechia
  • Novartis Investigative Site
    Praha 5, 150 06, Czechia
  • Novartis Investigative Site
    Praha, 12808, Czechia
  • Novartis Investigative Site
    Odense C, 5000, Denmark
  • Novartis Investigative Site
    Marseille, 13385, France
  • Novartis Investigative Site
    Mainz, 55131, Germany
  • Novartis Investigative Site
    Athens, 115 27, Greece
  • Novartis Investigative Site
    Thessaloniki, GR-54642, Greece
  • Novartis Investigative Site
    Guatemala City, 01011, Guatemala
  • Novartis Investigative Site
    Guatemala, 01010, Guatemala
  • Novartis Investigative Site
    Quetzaltenango, 9001, Guatemala
  • Novartis Investigative Site
    New Delhi, Delhi 110 017, India
  • Novartis Investigative Site
    New Delhi, Delhi 110 060, India
  • Novartis Investigative Site
    Padova, PD 35128, Italy
  • Novartis Investigative Site
    Toyoake city, Aichi 470 1192, Japan
  • Novartis Investigative Site
    Kitakyushu, Fukuoka 807-8556, Japan
  • Novartis Investigative Site
    Sendai city, Miyagi 980 8574, Japan
  • Novartis Investigative Site
    Kurashiki, Okayama 701-0192, Japan
  • Novartis Investigative Site
    Chuo, Yamanashi 409-3898, Japan
  • Novartis Investigative Site
    Seoul, Seocho Gu 06591, Korea, Republic of
  • Novartis Investigative Site
    Seoul, 04763, Korea, Republic of
  • Novartis Investigative Site
    Mexicali, Baja California Norte 21200, Mexico
  • Novartis Investigative Site
    Ciudad De Mexico, Mexico CP 14080, Mexico
  • Novartis Investigative Site
    Merida, Yucatan 97070, Mexico
  • Novartis Investigative Site
    Mexico, 06726, Mexico
  • Novartis Investigative Site
    Oslo, 0372, Norway
  • Novartis Investigative Site
    Santiago de Surco, Lima 33, Peru
  • Novartis Investigative Site
    Lipa City, Batangas 4217, Philippines
  • Novartis Investigative Site
    Iloilo, 5000, Philippines
  • Novartis Investigative Site
    Manila, 1008, Philippines
  • Novartis Investigative Site
    Quezon, 1102, Philippines
  • Novartis Investigative Site
    Coimbra, 3000 075, Portugal
  • Novartis Investigative Site
    Guimaraes, 4835-044, Portugal
  • Novartis Investigative Site
    Lisboa, 1069 166, Portugal
  • Novartis Investigative Site
    Porto, 4099-001, Portugal
  • Novartis Investigative Site
    Oradea, Jud Bihor 410619, Romania
  • Novartis Investigative Site
    Ramnicu Valcea, Valcea 240672, Romania
  • Novartis Investigative Site
    Bucharest, 022328, Romania
  • Novartis Investigative Site
    Bucuresti, 010 731, Romania
  • Novartis Investigative Site
    Bucuresti, 011172, Romania
  • Novartis Investigative Site
    Kazan, 420012, Russian Federation
  • Novartis Investigative Site
    Kemerovo, 650070, Russian Federation
  • Novartis Investigative Site
    Rostov On Don, 344022, Russian Federation
  • Novartis Investigative Site
    Saint Petersburg, 197022, Russian Federation
  • Novartis Investigative Site
    Yaroslavl, 150062, Russian Federation
  • Novartis Investigative Site
    Piestany, 92101, Slovakia
  • Novartis Investigative Site
    Barcelona, Catalunya 08036, Spain
  • Novartis Investigative Site
    Santiago De Compostela, Galicia 15706, Spain
  • Novartis Investigative Site
    Vigo, Pontevedra 36200, Spain
  • Novartis Investigative Site
    Stockholm, 17176, Sweden
  • Novartis Investigative Site
    St Gallen, 9007, Switzerland
  • Novartis Investigative Site
    Kaohsiung, 81346, Taiwan
  • Novartis Investigative Site
    Taichung, 40447, Taiwan
  • Novartis Investigative Site
    Taichung, 407219, Taiwan
  • Novartis Investigative Site
    Taoyuan, 33305, Taiwan
  • Novartis Investigative Site
    Bangkok, 10400, Thailand
  • Novartis Investigative Site
    Bangkok, 10700, Thailand
  • Novartis Investigative Site
    Bakırkoy Istanbul, 34147, Turkey

Showing the first 100 of 105 sites across 34 countries. Choose a country and city above to see the rest.

09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Novartis is committed to sharing access to patient-level data and supporting clinical documents from eligible studies with qualified external researchers. Requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to protect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2020 to primary completion in Sep 2023, 38 months.

Results were first posted in Oct 2024, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 27, 2019
First posted
Nov 29, 2019
StartActual
Jul 7, 2020
Primary completionActual
Sep 13, 2023
CompletionActual
Sep 13, 2023
Results first posted
Oct 10, 2024
Last update
May 16, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 16, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04181762
Responsible party
Sponsor
First posted
Nov 29, 2019
Start date
Jul 7, 2020
Primary completion
Sep 13, 2023
Completion
Sep 13, 2023
Results posted
Oct 10, 2024
Last update
May 16, 2025

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Secukinumab

Start the discussion